Available Technologies
# of Displayed Technologies: 3 / 3
Applied Category Filter (Click To Remove): Vaccines
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Mutant Hydrogenase Bacteria for Use against Enteric Pathogens
TS-015013 — Hydrogenase enzyme deficient bacterial strains that may be used as vaccines or attenuating agents for enteropathogenic diseases.
Enteric pathogens are responsible for an estimated two million deaths annually and cause millions more cases of diarrheal illness even in developed countries. When an individual contracts an enteric pathogen such as S. typhimurium, the infected individual will continue to shed the pathogen for up …
- College: College of Medicine (COM)
- Inventors: Gunn, John
- Licensing Officer: Taysavang, Panya
